Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vasomotor Symptoms Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen

NCT00332553
View directory record Official record
Conditions
Vasomotor Symptoms, Endometrial Safety
Interventions
Raloxifene, medroxyprogesterone acetate, estrogen, 17 beta estradiol
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 70 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 14, 2007 · Synced Jul 22, 2026, 5:07 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Stellate Ganglion Blockade in Post-Menopausal Women

NCT02907983
View directory record Official record
Conditions
Hot Flashes, Hot Flushes, Vasomotor Symptoms
Interventions
Stellate Ganglion Block Injection with Bupivicaine, Saline injection
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 70 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

NCT01361308
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
Brisdelle (paroxetine mesylate), Placebo capsules
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
40 Years and older · Female only
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
74
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)

NCT04090957
View directory record Official record
Conditions
Vasomotor Symptoms, Menopausal Symptoms
Interventions
Estetrol oral tablet, Placebo oral tablet
Drug
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,015 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
111
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

NCT05351892
View directory record Official record
Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
Interventions
Elinzanetant (BAY3427080)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 2 Interventional

Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

NCT03518138
View directory record Official record
Conditions
Vasomotor Symptoms (VMS)
Interventions
Q-122, Placebo
Drug
Lead sponsor
Que Oncology
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Woodstock, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

NCT05042362
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
55
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients

NCT00962585
View directory record Official record
Conditions
Menopause
Interventions
Placebo, S-equol
Drug
Lead sponsor
Ausio Pharmaceuticals, LLC
Industry
Eligibility
Female only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Louisville, Kentucky • Cincinnati, Ohio • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Results available

Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

NCT00446199
View directory record Official record
Conditions
Vasomotor Symptoms, Hot Flashes
Interventions
0.5mg DRSP / 0.5mg E2 (BAY86-4891), 0.25mg DRSP / 0.5mg E2 (BAY86-4891), Estradiol (E2 0.3mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women

NCT05813067
View directory record Official record
Conditions
Vasomotor Symptoms, Postmenopausal Disorders
Interventions
JDS-HF 3.0, Placebo
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Lake Worth, Florida • Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 3 Interventional

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

NCT00238732
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Jul 22, 2026, 5:07 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Vasomotor Symptoms and Cardiovascular Control

NCT02202707
View directory record Official record
Conditions
Vasomotor Symptoms, Cardiovascular Health
Interventions
Gabapentin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
45 Years to 58 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mindfulness-Based Stress Reduction for Hot Flashes

NCT01052454
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
Mindfulness-based stress reduction
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2010 · Synced Jul 22, 2026, 5:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study to Learn More About Vasomotor Symptoms Burden and Treatment Patterns in Menopausal Women Before and After Participating in OASIS Studies

NCT06949553
View directory record Official record
Conditions
Vasomotor Symptoms (VMS) Associated With Menopause
Interventions
No study intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 22, 2026, 5:07 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

NCT07218445
View directory record Official record
Conditions
Obesity, Menopause Hot Flashes
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
46 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 5:07 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)

NCT02049164
View directory record Official record
Conditions
Vasomotor Symptoms (VMS)
Interventions
AR08, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
41 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
San Diego, California • Colorado Springs, Colorado • Lakeworth, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Jul 22, 2026, 5:07 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial Assessing Safety of MF101 for Hot Flushes

NCT01300078
View directory record Official record
Conditions
Hot Flashes
Interventions
MF101
Drug
Lead sponsor
Bionovo
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
4
States / cities
Berkeley, California • Lincoln, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study - Impact of Traditional Acupuncture on Menopause

NCT00950482
View directory record Official record
Conditions
Menopause
Interventions
TA, AA, WC
Procedure · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women

NCT03640754
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
G-CSF, Placebo/Saline
Biological · Other
Lead sponsor
MenoGeniX, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Jul 22, 2026, 5:07 PM EDT
Recruiting Phase 2 Interventional

Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer

NCT06972875
View directory record Official record
Conditions
Prostate CA, Androgen Deprivation Therapy
Interventions
Fezolinetant
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women

NCT00683800
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
desvenlafaxine succinate (DVS) SR, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years and older · Female only
Enrollment
2,186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2011 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Not applicable Interventional

Nasal Saline Irrigation After Radiation Therapy for Oropharyngeal Cancer

NCT02338102
View directory record Official record
Conditions
Nasal Obstruction, Rhinitis, Vasomotor, Epistaxis
Interventions
Saline mixture
Other
Lead sponsor
Lisa Shnayder
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 4 Interventional Results available

Vortioxetine for Menopausal Depression

NCT02234362
View directory record Official record
Conditions
Depression, Menopause, Vasomotor Disturbance, Hot Flashes, Sleep
Interventions
vortioxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Jul 22, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms

NCT01942668
View directory record Official record
Conditions
Menopause
Interventions
Estradiol, Progesterone, Placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,845 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
119
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Jul 22, 2026, 5:07 PM EDT